Adverum Revenue Per Employee vs Market Capitalization Analysis

ADVM Stock

USD 11.53 0.20 1.71%

Trend analysis of Adverum Biotechnologies balance sheet accounts such as Short Long Term Debt Total of 63.9 M, Other Current Liabilities of 13.1 M or Total Current Liabilities of 15 M provides information on Adverum Biotechnologies' total assets, liabilities, and equity, which is the actual value of Adverum Biotechnologies to its prevalent stockholders. By breaking down trends over time using Adverum Biotechnologies balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Non Current Assets Total

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

About Adverum Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Adverum Biotechnologies at a specified time, usually calculated after every quarter, six months, or one year. Adverum Biotechnologies Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Adverum Biotechnologies and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Adverum currently owns. An asset can also be divided into two categories, current and non-current.

Adverum Biotechnologies Balance Sheet Chart

Adverum Biotechnologies Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Adverum Biotechnologies uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Adverum Biotechnologies' Liabilities And Stockholders Equity is very stable compared to the past year. As of the 16th of April 2024, Non Current Liabilities Total is likely to grow to about 67.9 M, while Total Current Liabilities is likely to drop about 15 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Adverum Biotechnologies assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Adverum Biotechnologies books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Adverum Biotechnologies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Adverum Biotechnologies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Adverum Biotechnologies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Adverum Biotechnologies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Adverum Biotechnologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.As of the 16th of April 2024, Sales General And Administrative To Revenue is likely to grow to 17.94, while Selling General Administrative is likely to drop about 31.8 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	153.6M	157.1M	121.7M	81.4M
Cost Of Revenue	4.6M	6.5M	5.6M	5.4M

Total Operating Expenses Cost Of Revenue

Adverum Biotechnologies fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Non Currrent Assets Other	Other Assets	Net Tangible Assets
Total Assets		0.63	0.26	0.74	0.94	0.18	0.65	-0.06	-0.61	0.56	0.35	0.66	-0.52	0.94	0.46	-0.19	0.6	0.64	0.82	0.65	0.61	0.94	0.31	0.12	0.43	0.84
Short Long Term Debt Total	0.63		0.68	0.84	0.38	-0.05	0.89	0.32	-0.83	0.35	0.07	0.9	-0.53	0.39	0.5	-0.33	0.93	0.6	0.8	0.93	0.92	0.41	0.71	0.58	0.84	0.33
Other Current Liab	0.26	0.68		0.69	-0.02	-0.3	0.57	0.29	-0.82	0.35	0.02	0.57	-0.23	0.01	-0.15	-0.12	0.67	0.44	0.61	0.62	0.68	0.02	0.89	0.94	0.84	0.06
Total Current Liabilities	0.74	0.84	0.69		0.55	-0.12	0.88	0.3	-0.89	0.72	0.06	0.89	-0.43	0.55	0.22	-0.41	0.84	0.83	0.95	0.91	0.84	0.56	0.72	0.5	0.76	0.47
Total Stockholder Equity	0.94	0.38	-0.02	0.55		0.32	0.42	-0.27	-0.33	0.48	0.46	0.42	-0.47	1.0	0.4	-0.03	0.31	0.49	0.66	0.42	0.33	1.0	-0.01	-0.13	0.11	0.82
Other Liab	0.18	-0.05	-0.3	-0.12	0.32		-0.31	-0.76	0.23	-0.13	0.74	-0.28	-0.23	0.35	0.04	0.45	-0.25	-0.18	-0.1	-0.21	-0.3	0.34	-0.28	-0.18	-0.32	-0.03
Property Plant And Equipment Net	0.65	0.89	0.57	0.88	0.42	-0.31		0.55	-0.8	0.47	-0.18	1.0	-0.34	0.41	0.54	-0.58	0.95	0.7	0.84	0.99	0.96	0.42	0.64	0.39	0.79	0.43
Net Debt	-0.06	0.32	0.29	0.3	-0.27	-0.76	0.55		-0.4	0.15	-0.91	0.54	0.31	-0.3	0.21	-0.58	0.54	0.24	0.25	0.48	0.56	-0.28	0.41	0.17	0.49	0.03
Retained Earnings	-0.61	-0.83	-0.82	-0.89	-0.33	0.23	-0.8	-0.4		-0.57	0.03	-0.81	0.34	-0.34	-0.2	0.36	-0.88	-0.73	-0.89	-0.84	-0.88	-0.36	-0.91	-0.68	-0.94	-0.46
Accounts Payable	0.56	0.35	0.35	0.72	0.48	-0.13	0.47	0.15	-0.57		0.03	0.47	-0.32	0.48	-0.08	-0.28	0.38	0.9	0.65	0.47	0.36	0.49	0.37	0.12	0.34	0.36
Cash	0.35	0.07	0.02	0.06	0.46	0.74	-0.18	-0.91	0.03	0.03		-0.17	-0.53	0.49	-0.03	0.42	-0.14	0.03	0.1	-0.1	-0.17	0.48	-0.08	0.09	-0.12	0.15
Non Current Assets Total	0.66	0.9	0.57	0.89	0.42	-0.28	1.0	0.54	-0.81	0.47	-0.17		-0.34	0.41	0.54	-0.56	0.96	0.7	0.85	0.99	0.96	0.43	0.65	0.4	0.79	0.43
Long Term Debt	-0.52	-0.53	-0.23	-0.43	-0.47	-0.23	-0.34	0.31	0.34	-0.32	-0.53	-0.34		-0.48	-0.2	0.23	-0.34	-0.37	-0.4	-0.37	-0.32	-0.48	-0.27	-0.21	-0.31	-0.35
Cash And Short Term Investments	0.94	0.39	0.01	0.55	1.0	0.35	0.41	-0.3	-0.34	0.48	0.49	0.41	-0.48		0.38	-0.01	0.31	0.48	0.66	0.41	0.33	1.0	0.01	-0.1	0.12	0.82
Net Receivables	0.46	0.5	-0.15	0.22	0.4	0.04	0.54	0.21	-0.2	-0.08	-0.03	0.54	-0.2	0.38		-0.19	0.52	0.25	0.33	0.51	0.5	0.39	-0.05	-0.16	0.27	0.37
Common Stock Shares Outstanding	-0.19	-0.33	-0.12	-0.41	-0.03	0.45	-0.58	-0.58	0.36	-0.28	0.42	-0.56	0.23	-0.01	-0.19		-0.53	-0.35	-0.3	-0.52	-0.53	-0.02	-0.43	0.07	-0.41	-0.25
Non Current Liabilities Total	0.6	0.93	0.67	0.84	0.31	-0.25	0.95	0.54	-0.88	0.38	-0.14	0.96	-0.34	0.31	0.52	-0.53		0.63	0.8	0.96	0.99	0.32	0.78	0.53	0.91	0.39
Other Current Assets	0.64	0.6	0.44	0.83	0.49	-0.18	0.7	0.24	-0.73	0.9	0.03	0.7	-0.37	0.48	0.25	-0.35	0.63		0.8	0.7	0.6	0.5	0.5	0.23	0.57	0.38
Other Stockholder Equity	0.82	0.8	0.61	0.95	0.66	-0.1	0.84	0.25	-0.89	0.65	0.1	0.85	-0.4	0.66	0.33	-0.3	0.8	0.8		0.87	0.81	0.67	0.66	0.43	0.73	0.65
Total Liab	0.65	0.93	0.62	0.91	0.42	-0.21	0.99	0.48	-0.84	0.47	-0.1	0.99	-0.37	0.41	0.51	-0.52	0.96	0.7	0.87		0.96	0.43	0.69	0.47	0.82	0.4
Property Plant And Equipment Gross	0.61	0.92	0.68	0.84	0.33	-0.3	0.96	0.56	-0.88	0.36	-0.17	0.96	-0.32	0.33	0.5	-0.53	0.99	0.6	0.81	0.96		0.34	0.78	0.54	0.9	0.43
Total Current Assets	0.94	0.41	0.02	0.56	1.0	0.34	0.42	-0.28	-0.36	0.49	0.48	0.43	-0.48	1.0	0.39	-0.02	0.32	0.5	0.67	0.43	0.34		0.03	-0.09	0.13	0.82
Property Plant Equipment	0.31	0.71	0.89	0.72	-0.01	-0.28	0.64	0.41	-0.91	0.37	-0.08	0.65	-0.27	0.01	-0.05	-0.43	0.78	0.5	0.66	0.69	0.78	0.03		0.78	0.94	0.2
Non Currrent Assets Other	0.12	0.58	0.94	0.5	-0.13	-0.18	0.39	0.17	-0.68	0.12	0.09	0.4	-0.21	-0.1	-0.16	0.07	0.53	0.23	0.43	0.47	0.54	-0.09	0.78		0.77	-0.08
Other Assets	0.43	0.84	0.84	0.76	0.11	-0.32	0.79	0.49	-0.94	0.34	-0.12	0.79	-0.31	0.12	0.27	-0.41	0.91	0.57	0.73	0.82	0.9	0.13	0.94	0.77		0.29
Net Tangible Assets	0.84	0.33	0.06	0.47	0.82	-0.03	0.43	0.03	-0.46	0.36	0.15	0.43	-0.35	0.82	0.37	-0.25	0.39	0.38	0.65	0.4	0.43	0.82	0.2	-0.08	0.29

Click cells to compare fundamentals

Adverum Biotechnologies Account Relationship Matchups

Adverum Biotechnologies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Other Current Liab	2.6M	1.3M	2.0M	16.8M	12.5M	13.1M
Total Current Liabilities	19.4M	20.9M	21.3M	32.2M	24.9M	15.0M
Total Stockholder Equity	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Other Liab	1.4M	48K	1.1M	1.0M	942.3K	895.2K
Property Plant And Equipment Net	45.8M	47.1M	119.1M	113.9M	67.0M	37.4M
Net Debt	(33.6M)	(31.7M)	68.8M	38.4M	36K	37.8K
Retained Earnings	(385.0M)	(502.5M)	(648.1M)	(802.6M)	(919.8M)	(873.8M)
Accounts Payable	4.1M	2.8M	1.4M	2.2M	1.9M	1.9M
Cash	65.9M	62.4M	34.2M	68.4M	75M	78.2M
Non Current Assets Total	46.9M	48.1M	122.6M	117.8M	70.2M	39.7M
Cash And Short Term Investments	166.0M	429.7M	305.2M	185.6M	96.5M	91.7M
Common Stock Shares Outstanding	6.4M	8.5M	9.8M	9.9M	10.1M	18.4M
Liabilities And Stockholders Equity	222.7M	482.6M	439.7M	308.4M	173.0M	247.9M
Non Current Liabilities Total	28.4M	27.3M	102.2M	94.6M	64.6M	67.9M
Other Current Assets	9.8M	4.7M	6.2M	5.0M	6.2M	4.0M
Other Stockholder Equity	560.7M	937.1M	965.0M	985.7M	1.0B	567.3M
Total Liab	47.8M	48.2M	123.5M	126.9M	89.5M	46.9M
Property Plant And Equipment Gross	24.9M	47.1M	132.2M	130.9M	81.5M	85.6M
Total Current Assets	175.9M	434.4M	317.1M	190.6M	102.8M	97.6M
Accumulated Other Comprehensive Income	(725K)	(261K)	(714K)	(1.5M)	(473K)	(496.7K)
Property Plant Equipment	24.9M	27.7M	33.1M	113.9M	130.9M	137.5M
Non Currrent Assets Other	11K	29K	250K	1.4M	1.2M	1.3M
Other Assets	1.0M	1.0M	3.5M	3.9M	4.5M	4.7M
Net Tangible Assets	175.0M	434.3M	316.2M	181.5M	208.7M	256.7M
Common Stock Total Equity	5K	6K	7K	10K	11.5K	6.5K
Retained Earnings Total Equity	(320.5M)	(385.0M)	(502.5M)	(648.1M)	(583.3M)	(554.1M)
Short Term Investments	100.1M	367.3M	271.0M	117.2M	21.5M	20.4M
Capital Surpluse	522.5M	560.7M	937.1M	965.0M	1.1B	599.6M
Short Term Debt	4.0M	4.5M	1.9M	13.2M	10.4M	6.1M
Common Stock	5K	6K	7K	10K	11.5K	7.4K
Non Current Liabilities Other	28.4M	27.3M	102.2M	1.0M	1.2M	1.1M
Net Invested Capital	175.0M	434.3M	316.2M	181.5M	83.5M	79.3M
Net Working Capital	156.5M	413.6M	295.8M	158.3M	77.9M	74.0M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adverum Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adverum Biotechnologies' short interest history, or implied volatility extrapolated from Adverum Biotechnologies options trading.

Pair Trading with Adverum Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adverum Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adverum Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Adverum Stock

0.64

EWTX

Edgewise Therapeutics Financial Report 9th of May 2024

Pair Corr

Moving against Adverum Stock

0.5

MRNA

Moderna Financial Report 2nd of May 2024

Pair Corr

The ability to find closely correlated positions to Adverum Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adverum Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adverum Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adverum Biotechnologies to buy it.

The correlation of Adverum Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adverum Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adverum Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Adverum Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Adverum Biotechnologies is a strong investment it is important to analyze Adverum Biotechnologies' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adverum Biotechnologies' future performance. For an informed investment choice regarding Adverum Stock, refer to the following important reports:

How To Invest In Adverum

Details

Is Adverum Stock a good investment?

Details

What is Adverum Biotechnologies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Adverum Stock, please use our How to Invest in Adverum Biotechnologies guide.

You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Adverum Stock analysis

When running Adverum Biotechnologies' price analysis, check to measure Adverum Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adverum Biotechnologies is operating at the current time. Most of Adverum Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adverum Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adverum Biotechnologies' price. Additionally, you may evaluate how the addition of Adverum Biotechnologies to your portfolios can decrease your overall portfolio volatility.

	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Stocks Directory Find actively traded stocks across global markets
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories

Is Adverum Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adverum Biotechnologies. If investors know Adverum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adverum Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.60)

Revenue Per Share

0.357

Quarterly Revenue Growth

(0.70)

Return On Assets

(0.32)

Return On Equity

(0.88)

The market value of Adverum Biotechnologies is measured differently than its book value, which is the value of Adverum that is recorded on the company's balance sheet. Investors also form their own opinion of Adverum Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adverum Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adverum Biotechnologies' market value can be influenced by many factors that don't directly affect Adverum Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Adverum Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adverum Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adverum Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Adverum Revenue Per Employee vs Market Capitalization Analysis

About Adverum Balance Sheet Analysis

Adverum Biotechnologies Balance Sheet Chart

Total Assets

Total Current Liabilities

Adverum Biotechnologies fundamental ratios Correlations

Adverum Biotechnologies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Adverum Biotechnologies fundamental ratios Accounts

Pair Trading with Adverum Biotechnologies

Moving together with Adverum Stock

Moving against Adverum Stock

Complementary Tools for Adverum Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.99	Non Current Assets Total

Other Assets	- 0.94	Retained Earnings
Property Plant Equipment	- 0.91	Retained Earnings
Cash	- 0.91	Net Debt
Other Stockholder Equity	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Total Current Liabilities
Property Plant And Equipment Gross	- 0.88	Retained Earnings